NanOlogy
  • Home
  • About
  • Technology
  • Development
    • Investigational Drugs
    • Pipeline
    • Clinical Trials
    • Partnering Opportunities
  • News & Publications
  • Contact Us
    • Partnering Opportunities
    • Physicians and Patients
Post placeholder image
October 11, 2023 in NanOlogy in the News

OncLive: LSAM-PTX Demonstrates Disease Control, Safety in Locally Advanced Pancreatic Cancer

Wilson PJ 0 Like Post Comments Off on OncLive: LSAM-PTX Demonstrates Disease Control, Safety in Locally Advanced Pancreatic Cancer
Read More
Post placeholder image
September 16, 2021 in NanOlogy in the News

OncLive: LSAM-DTX Effective and Safe in NMIBC Using Direct, Multifaceted Approach

NanOlogy 0 Like Post Comments Off on OncLive: LSAM-DTX Effective and Safe in NMIBC Using Direct, Multifaceted Approach
Read More
Post placeholder image
September 16, 2021 in NanOlogy in the News

Target Oncology: Direct and Multifaceted LSAM-DTX Treatment May Be Safe and Effective in NMIBC

NanOlogy 0 Like Post Comments Off on Target Oncology: Direct and Multifaceted LSAM-DTX Treatment May Be Safe and Effective in NMIBC
Read More
Post placeholder image
March 26, 2021 in NanOlogy in the News, Uncategorized

JACS: Surgery is a viable treatment for pancreatic cancer patients especially after chemotherapy

NanOlogy 0 Like Post Comments Off on JACS: Surgery is a viable treatment for pancreatic cancer patients especially after chemotherapy
Read More
January 9, 2020 in NanOlogy in the News

Current Urology Reports: Current Clinical Trials in Non-muscle-Invasive Bladder Cancer: Heightened Need in an Era of Chronic BCG Shortage

NanOlogy 0 Like Post Comments Off on Current Urology Reports: Current Clinical Trials in Non-muscle-Invasive Bladder Cancer: Heightened Need in an Era of Chronic BCG Shortage

Current Clinical Trials in Non-muscle-Invasive Bladder Cancer: Heightened Need in an Era of Chronic BCG Shortage

Read More
May 7, 2019 in NanOlogy in the News

Drug Development Technology: NanOlogy Starts Enrollment in NanoDoce’s Phase I/II Trial

NanOlogy 0 Like Post Comments Off on Drug Development Technology: NanOlogy Starts Enrollment in NanoDoce’s Phase I/II Trial
Read More
January 11, 2019 in Home Page, NanOlogy in the News

NanOlogy Named to BioSpace Top 20 Life Science Startups to Watch in 2019

NanOlogy 1 Like Post Comments Off on NanOlogy Named to BioSpace Top 20 Life Science Startups to Watch in 2019
Read More
November 6, 2018 in Home Page, NanOlogy in the News

Wuxi AppTec: Small Molecule Chemotherapy May Play a Big Role in Cancer Immunotherapy

NanOlogy 1 Like Post Comments Off on Wuxi AppTec: Small Molecule Chemotherapy May Play a Big Role in Cancer Immunotherapy
Read More
Post placeholder image
August 29, 2018 in NanOlogy in the News

Drug Development: Targeted Delivery of Submicron Particle Cancer Chemotherapy: Helping Shift the Immunotherapy Paradigm

NanOlogy 0 Like Post Comments Off on Drug Development: Targeted Delivery of Submicron Particle Cancer Chemotherapy: Helping Shift the Immunotherapy Paradigm
Read More
Post placeholder image
May 30, 2018 in NanOlogy in the News

Drug Delivery: NanOlogy Touts Preclinical Data for Inhaled NanoPac Cancer Drug

NanOlogy 0 Like Post Comments Off on Drug Delivery: NanOlogy Touts Preclinical Data for Inhaled NanoPac Cancer Drug
Read More
Post placeholder image
May 3, 2018 in NanOlogy in the News

Boston Business Journal: NanOlogy Completes Dose Escalation Portion of Phase 2 Clinical Trial of NanoPac for Treatment of Prostate Cancer

NanOlogy 0 Like Post Comments Off on Boston Business Journal: NanOlogy Completes Dose Escalation Portion of Phase 2 Clinical Trial of NanoPac for Treatment of Prostate Cancer
Read More
Post placeholder image
April 9, 2018 in NanOlogy in the News

BioCentury: Tiny Taxanes – How Nanology’s Particle Production Technology Created Submicron Chemotherapy

NanOlogy 0 Like Post Comments Off on BioCentury: Tiny Taxanes – How Nanology’s Particle Production Technology Created Submicron Chemotherapy
Read More
Post placeholder image
March 5, 2018 in NanOlogy in the News

Drug Delivery: NanOlogy looks to transform chemotherapy with localized delivery platform

NanOlogy 0 Like Post Comments Off on Drug Delivery: NanOlogy looks to transform chemotherapy with localized delivery platform
Read More
Post placeholder image
February 28, 2018 in NanOlogy in the News

Drug Development: NanOlogy Submicron Particle Platform Transforms Systemic Chemotherapy Into Local Delivery

NanOlogy 0 Like Post Comments Off on Drug Development: NanOlogy Submicron Particle Platform Transforms Systemic Chemotherapy Into Local Delivery
Read More
Post placeholder image
February 14, 2018 in NanOlogy in the News

DermWire: NanOlogy Enrolls First Patient in Clinical Trial for Cutaneous Metastases

NanOlogy 0 Like Post Comments Off on DermWire: NanOlogy Enrolls First Patient in Clinical Trial for Cutaneous Metastases
Read More
Post placeholder image
February 5, 2018 in NanOlogy in the News

Houston Business Journal: NanOlogy to Update Clinical Program at BIO CEO Conference

NanOlogy 0 Like Post Comments Off on Houston Business Journal: NanOlogy to Update Clinical Program at BIO CEO Conference
Read More
Post placeholder image
January 3, 2018 in NanOlogy in the News

PharmaVOICE: Next-Generation Nanomedicines

NanOlogy 0 Like Post Comments Off on PharmaVOICE: Next-Generation Nanomedicines
Read More
Post placeholder image
December 19, 2017 in NanOlogy in the News

Drug Delivery Business: NanOlogy takes nanoparticle tech into Phase II trials

NanOlogy 0 Like Post Comments Off on Drug Delivery Business: NanOlogy takes nanoparticle tech into Phase II trials
Read More
Post placeholder image
November 20, 2017 in NanOlogy in the News

Clinical Leader: Trial Aims To Kill Cancer Without Chemotherapy Side Effects

NanOlogy 0 Like Post Comments Off on Clinical Leader: Trial Aims To Kill Cancer Without Chemotherapy Side Effects
Read More
Post placeholder image
November 13, 2017 in NanOlogy in the News

DDNEWS: New Cancer Answer

NanOlogy 0 Like Post Comments Off on DDNEWS: New Cancer Answer
Read More
Prev12Next
NanOlogy

NanOlogy investigational drugs have not yet been proven to be safe and effective in accordance with the requirements of the U.S. FDA and are not approved by FDA or any other jurisdiction for commercial distribution. NanOlogy, NanoPac, and NanoDoce are trademarks of NanOlogy, LLC.    Purcision is a trademark to CritiTech, Inc.  © NanOlogy LLC      Legal